SAN DIEGO—Higher levels of endogenous testosterone may associated with an increased risk of coronary heart disease (CHD) in men older than 65 years, according to a large U.S. multi-center study ...

Genomic characterization of locally recurrent prostate cancer after radiation therapy.

Aurobindo Pharma’s subsidiary, Eugia Pharma Specialities, has received the Food and Drug Administration’s permission for Testosterone Cypionate Injection 1,000 mg/10 ml (100 mg/ml) and 2,000 mg/10 ml ...

LPCN 1021 is a new twice-a-day oral testosterone replacement therapy intended to treat men with a deficiency or absence of endogenous testosterone. The FDA cited deficiencies in the dosing algorithm ...

Aviva Bio is advancing AVA-291 (d3-T) as a differentiated testosterone in a broad development program addressing multiple ...

TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP) today announced the Health Canada approval of NATESTO™, the first and only nasal gel for testosterone replacement therapy in ...

Please provide your email address to receive an email when new articles are posted on . Men with a testosterone concentration below 7.4 nmol/L had a greater risk for mortality. The study “resolves ...